Epstein–Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients

References

• Bortolin MT, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S, Tedeschi R, De Paoli P. (2006). Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 233:247–254.
   PubMedGoogle Scholar
• Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614–1619.
   PubMed Web of Science ®Google Scholar
• Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC. (1990). Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol 28:2398–2402.
   PubMedGoogle Scholar
• Devi BC, Pisani P, Tang TS, Parkin DM. (2004). High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 13:482–486.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin DM. (2001). Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon: IARC Press.
   Google Scholar
• Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC. (2006). Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J Clin Pathol 59:537–541.
   PubMedGoogle Scholar
• Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461–2470.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. (1999a). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188–1191.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. (1999b). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59:5452–5455.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ. (2000a). Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60:6878–6881.
   PubMed Web of Science ®Google Scholar
• Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, Huang DP. (2000b). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60:2351–2355.
   PubMedGoogle Scholar
• Lo YM, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, Chung SC. (2001). Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 7:1856–1859.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, Eds. (2002). Cancer Incidence in Five Continents. Volume VIII. Lyon: IARC Scientific Publications No. 155.
   Google Scholar
• Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350–1354.
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM. (2005). Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43:3066–3073.
   PubMed Web of Science ®Google Scholar
• Tan EL, Selvaratnam G, Kananathan R, Sam CK. (2006). Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 6:227.
   PubMed Web of Science ®Google Scholar
• Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY, Liang KL, Chen KW, Wu CT, Lin JC. (2010). Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16:1016–1024.
   PubMed Web of Science ®Google Scholar
• Yu MC, Yuan JM. (2002). Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12:421–429.
   PubMed Web of Science ®Google Scholar